CD45.2 is an alloantigen of CD45, also known as leukocyte common antigen or Ly-5 and is a transmembrane glycoprotein tyrosine phosphatase expressed on all nucleated hematopoietic cells. CD45.2 is expressed by all leukocytes and the mouse strains expressing Ly5.2 (e.g BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). It is characterized by several isoforms and is distributed according to cell type and degree of cellular differentiation. CD45 has shown to play a role in the initiation of T-cell receptor signaling via activation of the tyrosine kinases Lck and Fyn. Deficiency of CD45 results in T and B-lymphocyte dysfunction characterized by severe combined immune deficiency. CD45 immunoreactivity is characteristic of autoimmune diseases and cancer such as non-Hodgkin’s lymphomas.
Anti-CD45.2-SAP is a bonded conjugate of biotinylated anti-CD45.2 and the secondary conjugate Streptavidin-ZAP (IT-27) containing the ribosome-inactivating protein, saporin. Anti-CD45.2-SAP specifically eliminates cells expressing CD45.2 in mice.
keywords: CD45, CD45.2, Anti-CD45, Anti-CD45.2, streptavidin, biotinylated, saporin